What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm Saturday 9am - 5pm Sunday 9am - 5pm

Friends of Cancer Research

Home
United States
Washington D.C., DC
Friends of Cancer Research

Friends of Cancer Research powers advances in science and policy that speed life-saving treatments to patients.

Mission
Friends of Cancer Research powers advances in science and policy that speed life-saving treatments to patients. About Us
Friends of Cancer Research aims to accelerate cutting edge cancer care that both extends and improves quality of life for patients. To accomplish this, we leverage groundbreaking collaborations, generate scientific evidence, and integrate patient input to shape public policy. How we work at Friends of Cancer Research:
We identify problems standing in the way of the best science reaching patients. We generate the evidence necessary to understand a problem. We create policy solutions to address and overcome that problem.

12/19/2025

Next year, over two million Americans will face a cancer diagnosis. Advancing access to treatments is critical to ensure that every patient receives high-quality care. At Friends of Cancer Research, our research is accelerating the development of cutting-edge therapies and helping to bring lifesaving treatments to patients nationwide.

As we look ahead to 2026, this work is more important than ever. Learn more about our upcoming projects and visit: https://friendsofcancerresearch.org/projects/.

Your support makes the difference between promising research and life-saving reality. Make a gift today to help us reach this goal: https://friendsofcancerresearch.org/donate-friends-of-cancer-research/.

Together, we can help speed life-saving treatments to patients.

12/17/2025

How can we rigorously demonstrate that each drug in a combination therapy contributes meaningfully to patient benefit?

As oncology combination therapies advance rapidly, ensuring each component provides meaningful contribution of effect (COE) is essential—both to maximize therapeutic benefit and avoid unnecessary toxicity. While factorial designs with four arms (A, B, A+B, & Control) remain the most rigorous approach for isolating each component's contribution, they may be infeasible due to recruitment challenges, operational complexity, prolonged timelines, or when sufficient evidence suggests a component is inactive.

During the "Trial Designs for Combination Drug Development" session at our 2025 Annual Meeting, panelists discussed alternative trial designs—such as adaptive, 3-arm, 2-arm, and descriptive comparison approaches—that still provide robust evidence for each agent's COE.

Read the accompanying white paper, which features expert input from regulatory agencies, pharmaceutical companies, academia, and patient advocacy organizations, to explore best practices for generating COE data: https://bit.ly/3LcLaqf.

12/15/2025

Read our latest quarterly Advocate Newsletter! Catch up on important developments across oncology, new projects from Friends of Cancer Research, and take a look back at our 2025 Year in Review.

This issue features:
• Key highlights from our 2025 Annual Meeting
• Upcoming events from Friends of Cancer Research and partner organizations
• Exciting news about our Spanish-language version of ProgressforPatients.org

Read the latest issue and subscribe to stay informed: https://bit.ly/4iXzqVa.

12/11/2025

How can we accelerate drug development in rare cancers while maximizing insights from every patient?

Rare cancer populations present unique challenges: limited patient numbers, heterogeneous disease biology, and constrained resources make phased-based development approaches inefficient. Sequential evaluation across distinct trial phases can slow evidence generation and delay patient access to potentially life-saving therapies.

During the "Seamless Clinical Trial Designs in Rare Cancers" session at our 2025 Annual Meeting, panelists examined how to design seamless trials that are both scientifically rigorous and operationally viable, what types of data can support regulatory decision-making in the absence of a control arm, and how thoughtful endpoint selection and flexible trial design can help reduce patient burden while maintaining confidence in results.

Read the accompanying white paper to explore critical design considerations—including patient engagement, regulatory dialogue, dosage optimization, endpoint selection, adaptive features, and operational planning—which are essential for successful implementation of seamless approaches: https://bit.ly/4hv2PFP.

12/09/2025

Looking for a meaningful way to use some downtime this holiday season?

ProgressforPatients.org is a free, online advocacy education program designed to empower patients, caregivers, and advocates with essential knowledge about the drug development process—all in under two hours.

Discover how a drug goes from the lab to FDA approval, explore real stories of how patients have used their voices to enact change, and learn to effectively communicate with researchers, developers, and regulators.

Learn at your own pace and gain the tools to become a more impactful advocate.

12/04/2025

Early endpoints are an important tool for accelerating the development of promising therapies and getting treatments to patients faster. Friends of Cancer Research is hosting a public meeting, Modernizing Oncology Endpoints: Pathways for Evidence and Policy, to review the current landscape and application of evolving early endpoints—such as ctDNA and AI-based tumor assessments—and explore how they may improve trial efficiency and inform regulatory decision-making.

View our agenda and register now to secure your spot: https://bit.ly/487Mv9B.

12/03/2025

How can regulatory, manufacturing, and financial frameworks be better aligned to support genetically modified cell therapies developed for small or rare patient populations?

A new Journal for ImmunoTherapy of Cancer commentary from Friends of Cancer Research and Parker Institute for Cancer Immunotherapy outlines strategies to tailor manufacturing and quality expectations for therapies designed for rare patient populations, implement adaptable regulatory approaches that reflect the realities of rare disease drug development, and develop sustainable financial mechanisms to support continued development and access.

Read the full commentary to learn more: https://jitc.bmj.com/content/13/12/e013518.

12/02/2025

On behalf of everyone at Friends of Cancer Research, we want to express our deepest gratitude for your unwavering support. Your partnership and support have been instrumental in accelerating research and expanding access to innovative therapies for patients everywhere.

As we approach 2026, we are excited to advance critical initiatives aimed to reduce clinical trial times, lower costs of drug development, improve accuracy of tumor assessments, and accelerate access to new treatments.

Please consider making a donation today to help continue our important work: https://friendsofcancerresearch.org/donate-friends-of-cancer-research/.

Together, we are advancing the science and policy that speed life-saving treatments to patients. Thank you for being part of this vital mission.

12/01/2025

During our Advocates Webinar, our Advisory Advocates discussed how patient voices shaped the 2025 Annual Meeting. From seamless trial designs for rare cancers to selecting comparator arms in global trials, their lived experiences brought critical insights to the table. As patients, survivors, and caregivers, they understand firsthand what matters most. Read the recap blog to learn how early patient engagement strengthens clinical research and regulatory decision-making: https://bit.ly/49L3d11.

11/25/2025

Not sure what ctDNA is, why endpoints matter, or how to interpret the findings? Our companion blog to our recently published ctDNA study defines key terminology, breaks down the methodology and results, and explains the clinical implications and remaining questions—all in accessible language.

Read the blog to learn about recent findings from our ctMoniTR Project and how ctDNA may be used to help get better drugs to patients faster: https://bit.ly/4nUTCby.

11/17/2025

Happening Now! Our free Advocate Webinar is live on YouTube! https://bit.ly/4i5ATs5

Join our Advisory Advocates as they explore key takeaways from our 2025 Annual Meeting and highlight what patients, caregivers, and advocates can learn.

During the Annual Meeting, Kristin McJunkins highlighted patients' willingness to participate in clinical trials, informed consent, and transparent communication. Now, she and other advocates are diving deeper into these insights as they discuss how evolving treatment landscapes and control arm selection can impact patients.

Join now or watch on-demand later!

11/14/2025

At the Friends of Cancer Research 2025 Annual Meeting, Carol Vallett emphasized how reducing burdens on patients participating in clinical trials, such as minimizing frequency of blood draws and reducing travel distances for treatment, can improve trial experience and expand access.

Building on these conversations, we invite patient advocates and caregivers to join our free Advocate Webinar on Monday, November 17 from 1pm-2pm ET!

This free session will revisit the three panel topics discussed at the Annual Meeting, with an emphasis on the patient advocate perspective and experience, and includes:
• Seamless Trial Designs for Rare Cancer Drug Development
• Trial Designs for Combination Drug Development
• Control Arm Selection for Multi-Regional Clinical Trials

Hear directly from Friends of Cancer Research Advisory Advocates and deepen your understanding of some of the most pressing topics in cancer research and regulation. Register today! https://friendsofcancerresearch.org/event/advocates-webinar-annual-meeting-2025/

Address

1800 M Street NW
Washington D.C., DC
20036

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm
Saturday	9am - 5pm
Sunday	9am - 5pm

Telephone

(202) 944-6700

Website

https://friendsofcancerresearch.org/

Alerts

Be the first to know and let us send you an email when Friends of Cancer Research posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Washington D.C.?